{
    "clinical_study": {
        "@rank": "90883", 
        "arm_group": [
            {
                "arm_group_label": "PF582", 
                "arm_group_type": "Experimental", 
                "description": "PF582 is provided as single use vials and will be administered by intra\u2010vitreal injection on Day 1, 28 and 56."
            }, 
            {
                "arm_group_label": "Lucentis", 
                "arm_group_type": "Active Comparator", 
                "description": "Lucentis\u00ae is provided as single use vials and will be administered by intra\u2010vitreal injection on Day 1, 28 and 56."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to test if PF582 (ranibizumab) is safe and similar to Lucentis\n      (ranibizumab). Participants will have a screening visit to check for eligibility. Eligible\n      participants will receive either PF582 or Lucentis, by injection into one eye on study Day\n      1, 28 and 56. Visits will be conducted on Day 2, 7, 14 80 and at 6 and 12 months. During the\n      study participants will undergo the following procedures: height, weight and vital signs\n      (blood pressure, pulse, temperature, breathing rate) measurement; medical and surgical\n      history and concomitant medications; adverse event monitoring; physical examinations; eye\n      tests (reading chart, measurement of retinal thickness [via pictures of the retina] and\n      examination of the eye's blood vessels, via pictures taken following injection of a dye into\n      the arm), blood collection and a urine pregnancy test, where applicable."
        }, 
        "brief_title": "Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Age Related Macular Degeneration (AMD)", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "detailed_description": {
            "textblock": "To evaluate the safety and tolerability of PF582, compared to that of Lucentis (registered\n      trademark) in patients with neovascular AMD. This will be done by assessment of vital signs,\n      physical examination, laboratory blood tests and adverse events. Possible adverse events\n      include: eye irritation/discomfort, redness/itching eye, eye dryness, abnormal sensation in\n      eye; lens clouding; pain/irritation at injection site; increased tear production;\n      'floaters'; sore throat, nasal congestion, headache, joint pain, flu, fatigue,\n      breathlessness, dizziness, pale skin, anxiety, cough, nausea and allergic reactions.\n\n      Because PF582 is very similar to Lucentis it is expected to have similar adverse effects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226550 years\n\n          -  Presence in the study eye (one eye per patient) of previously untreated active\n             subfoveal CNV due to AMD, with presence of leakage, as seen on FA, and of fluid, as\n             seen on spectral\u2010domain OCT, located either within or below the retina, or below the\n             retinal pigment epithelium\n\n          -  Visual acuity between 20/25 and 20/320 being measured using the Early treatment\n             diabetic retinopathy study (ETDRS) protocol1 (chart at 4 meters) before pupil\n             dilation.\n\n          -  Neovascularization, fluid, or haemorrhage under the fovea.\n\n          -  Fibrosis < 50% of total lesion area\n\n          -  At least 1 drusen (>63\u03bcm) in either eye or late AMD in fellow eye.\n\n          -  Female subjects must be of non\u2010childbearing potential, meeting at least one of the\n             following criteria:\n\n          -  Amenorrheal for 12 months (Menopause confirmed by FSH and LH levels as defined by the\n             established reference ranges), or taking oral contraception for at least 3 months, or\n             surgically sterile for at least the past 3 months, or Receiving a stable dose of\n             implanted or injectable contraceptive for at least     3 months\n\n        Exclusion Criteria:\n\n          -  Previous treatment for CNV in study eye, including antivascular endothelial growth\n             factor(VEGF) medication\n\n          -  Other progressive retinal disease in the study eye, or the non\u2010study eye, likely to\n             compromise Visual Acuity assessment.\n\n          -  Contraindications to injections with Lucentis\u00ae\n\n          -  Sub\u2010retineal Haemorrhage > 50% of lesion\n\n          -  Fibrosis or retrofoveolar atrophy\n\n          -  History of retrofoveolar laser photocoagulation\n\n          -  Previous Lucentis\u00ae treatment\n\n          -  Any other treatment (photocoagulation, phototherapy, radiotherapy, surgery,\n             thermotherapy) in the last 3 months\n\n          -  Aphaky, vitrectomy\n\n          -  Active or suspected ocular or periocular infection\n\n          -  Active intraocular inflammation\n\n          -  Active systemic infection\n\n          -  History of stroke or congestive heart failure\n\n          -  Any other clinical significant illness or abnormalities that would compromise the\n             safety of the participant\n\n          -  Inability to comply with study or follow up procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121353", 
            "org_study_id": "PF582-CLIN-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lucentis", 
                "description": "Single\u2010use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha\u2010trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra\u2010vitreal", 
                "intervention_name": "Lucentis", 
                "intervention_type": "Drug", 
                "other_name": "ranibizumab"
            }, 
            {
                "arm_group_label": "PF582", 
                "description": "Single\u2010use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha\u2010trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra\u2010vitreal", 
                "intervention_name": "PF582", 
                "intervention_type": "Drug", 
                "other_name": "ranibizumab"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Age related macular degeneration", 
            "AMD", 
            "Wet AMD", 
            "Eye conditions", 
            "CFT", 
            "OCT", 
            "CNV", 
            "FA", 
            "Ocular", 
            "Eye", 
            "Disorder of the eye"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "contact": {
                    "email": "peteranddandy@paradise.net.nz", 
                    "last_name": "Peter Hadden, MD", 
                    "phone": "+64 9 522 2125"
                }, 
                "facility": {
                    "address": {
                        "city": "Remuera", 
                        "country": "New Zealand", 
                        "state": "Auckland", 
                        "zip": "1050"
                    }, 
                    "name": "Eye Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pjpolk@pjpolk.co.nz", 
                    "last_name": "Philip Polkinghorne, MD", 
                    "phone": "+64 9 529 2480"
                }, 
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1050"
                    }, 
                    "name": "Auckland Eye 8 St Marks Road Remuera Auckland 1050"
                }, 
                "investigator": {
                    "last_name": "Philip Polkinghorne, Prof/MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "New Zealand"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Phase 1/2, Double Blind, Parallel Group, Controlled Study of the Safety, Tolerability and Preliminary Efficacy Evaluation of Intravitreally Administered Pfenex Ranibizumab Biosimilar Versus Lucentis for the Treatment of Neovascular AMD", 
        "other_outcome": {
            "description": "To demonstrate the biosimiliarity between PF582 and the reference compound (Lucentis), based on pharmacodynamics (PD) parameters. This will be assessed by measuring retinal thickness or central foveal thickness (CFT), assessed by optical coherence tomography (OCT)), Leakage from choroidal neovascularization (CNV) assessed by fluorescein angiography (FA).", 
            "measure": "To demonstrate the biosimiliarity between PF582 and the reference compound (Lucentis), based on pharmacodynamics (PD) parameters.", 
            "safety_issue": "No", 
            "time_frame": "Up to 12 months"
        }, 
        "overall_official": {
            "last_name": "Philip Polkinghorne, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "New Zealand: Medsafe", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety and tolerability of PF582, compared to that of Lucentis (registered trademark) in patients with neovascular AMD. This will be done by assessment of vital signs, physical examination, laboratory blood tests and adverse events. Possible adverse events include: eye irritation/discomfort, redness/itching eye, eye dryness, abnormal sensation in eye; lens clouding; pain/irritation at injection site; increased tear production; 'floaters'; sore throat, nasal congestion, headache, joint pain, flu, fatigue, breathlessness, dizziness, pale skin, anxiety, cough, nausea and allergic reactions. Because PF582 is very similar to Lucentis it is expected to have similar adverse effects.", 
            "measure": "To evaluate the safety and tolerability of PF582", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121353"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To demonstrate the biosimiliarity between PF582 and the reference compound (Lucentis) based on pharmacokinetics (PK). This will be done by collection and analysis of PK blood samples.", 
                "measure": "To demonstrate the biosimiliarity between PF582 and Lucentis based on PK", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "description": "Preliminary analysis of efficacy, as evaluated by mean change in visual acuity between baseline and Day 80 assessment, and proportion of patients with a change in visual acuity of 15 letters or more", 
                "measure": "To demonstrate biosimilarity between PF582 and reference compound (Lucentis)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Pfenex, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfenex, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}